Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: GlobeNewswire
THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain. "We are pleased that the initial clinical data for LX9211 in the multiple ascending dose study supports continued advancement of the drug," said Praveen Tyle, Ph.D., executive vice president of research and development at Lexicon. "LX9211 was well tolerated with dose proportional pharmacokinetics, similar to what was seen in the single ascending dose study. We expect to initiate a proof-of-concept study for LX9211 early next year.” The randomized, double-blind, placebo-controlled, multiple ascending dose Phase 1 study was performed to evaluate the safety, tolerability and pharmacokinetics of orally administered LX9211 in healthy volunteers. The study was co
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)GlobeNewswire
- Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)GlobeNewswire
LXRX
Earnings
- 11/12/24 - Miss
LXRX
Sec Filings
- 12/16/24 - Form 3
- 12/9/24 - Form SC
- 12/2/24 - Form 4
- LXRX's page on the SEC website